Lithium

Active ingredient: Lithium Citrate

In short: Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older Maintenance treatment in patients 7 years and older

Forms & strengthsEach 5 mL of clear, colorless lithium oral solution USP contains 8 mEq lithium ion (Li +) (equivalent to the amount of lithium in 300 mg of lithium carbonate).
LabelRemedyrepack Inc.
Label updatedOct 26, 2026

What is Lithium used for?

Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder:

Treatment of acute manic and mixed episodes in patients 7 years and older

Maintenance treatment in patients 7 years and older

âš  Boxed warning (FDA's strongest warning)

Lithium toxicity is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations. Facilities for prompt and accurate serum lithium determinations should be available before initiating treatment

.

Lithium dosage

Before initiating treatment with lithium, renal function, vital signs, serum electrolytes, and thyroid function should be evaluated. Concurrent medications should be assessed, and if the patient is a woman of childbearing potential, pregnancy status and potential should be considered.

See Table 1 for dosage recommendations for acute and maintenance treatment of bipolar I disorder in adult and pediatric patients (7 to 17 years).

Obtain serum lithium concentration assay after 3 days, drawn 12 hours after the last oral dose and regularly until patient is stabilized. Fine hand tremor, polyuria, and thirst may occur during initial therapy for the acute manic phase and may persist throughout treatment. Nausea and general discomfort may also appear during the first few days of lithium administration. These adverse reactions may subside with continued treatment, concomitant administration with food, or temporary reduction or cessation of dosage.

Patient Group | Formulation | Starting Dose | Dose Titration | Acute Goal | Maintenance Goal

Serum Level | Usual Dose | Serum Level | Usual Dose

Adult and Pediatric Patients over 30 kg | Liquid | 8 mEq

(5 mL) three times daily | 8 mEq

(5 mL) every 3 days | 0.8 to 1.2 mEq/L | 16 mEq (10mL) two to three times daily | 0.8 to 1.0 mEq/L | 8 to 16 mEq (5 to 10 mL) two to three times daily

Pediatric Patients 20 to 30 kg | Liquid | 8 mEq

(5 mL) twice daily | 8 mEq

(5 mL) weekly | 16 to 40 mEq (10 to 25 mL) in divided doses daily | 16 to 32 mEq (10 to 20 mL) in divided doses daily

Each 5 mL of Lithium Oral Solution contains 8 mEq of lithium ion (Li

+) which is equivalent to the amount of lithium in 300 mg of lithium carbonate. See Table 2 for lithium carbonate and lithium oral solution dose conversion.

Table 2. Lithium Carbonate and Lithium Oral Solution Dose Conversion

Lithium Carbonate Tablets or Capsules | Lithium Oral Solution

150 mg | 4 mEq (2.5 mL)

300 mg | 8 mEq (5 mL)

600 mg | 16 mEq (10 mL)

Blood samples for serum lithium determination should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 12 hours after the previous dose). Total reliance must not be placed on serum concentrations alone. Accurate patient evaluation requires both clinical and laboratory analysis.

In addition to regular monitoring of serum lithium concentrations for patients on maintenance treatment, serum lithium concentrations should be monitored after any change in dosage, concurrent medication (e.g., diuretics, non-steroidal anti-inflammatory drugs, renin-angiotensin system antagonists, or metronidazole), marked increase or decrease in routinely performed strenuous physical activity (such as an exercise program) and in the event of a concomitant disease

. …

How to take Lithium — instructions & advice from the label

Advise the patient to read FDA-approved patient labeling (Medication Guide).

Dosage and Administration:

Advise patients that lithium is a mood stabilizer, and should only be taken as directed. Emphasize the importance of compliance with the prescribed treatment and to not adjust the dose of lithium without first consulting their healthcare provider. Inform patients that they will need to have regular blood draws to determine if their dose of lithium is appropriate.

Instruct patients not to double the dose if a dose is missed, due to the complexity of individualized dosing and potential for lithium toxicity

.

Lithium Toxicity:

Inform patients on adverse reactions related to lithium toxicity that require medical attention. Advise patients to discontinue lithium treatment and contact their healthcare provider if clinical signs of lithium toxicity such as diarrhea, vomiting, tremor, lack of muscle coordination, drowsiness, abnormal heart rhythm or muscular weakness occur

.

Lithium-Induced Polyuria:

Counsel patients on the adverse reactions related to lithium-induced polyuria, when to seek medical attention, and the importance of maintaining normal diet with salt and staying hydrated

. …

Warnings & precautions

Do not take this medicine if: Lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium citrate products

.

The toxic concentrations for lithium (≥1.5 mEq/L) are close to the therapeutic range (0.8 to 1.2mEq/L). Some patients abnormally sensitive to lithium may exhibit toxic signs at serum concentrations that are considered within the therapeutic range

. Lithium may take up to 24 hours to distribute into brain tissue, so occurrence of acute toxicity symptoms may be delayed.

Neurological signs of lithium toxicity range from mild neurological adverse reactions such as fine tremor, lightheadedness, lack of coordination, and weakness; to moderate manifestations like giddiness, apathy, drowsiness, hyperreflexia, muscle twitching, ataxia, blurred vision, tinnitus, and slurred speech; and severe manifestations such as clonus, confusion, seizure, coma, and death. In rare cases, neurological sequelae may persist despite discontinuing lithium treatment and may be associated with cerebellar atrophy. Cardiac manifestations involve electrocardiographic changes, such as prolonged QT interval, ST and T-wave changes and myocarditis. Renal manifestations include urine concentrating defect, nephrogenic diabetes insipidus, and renal failure. Respiratory manifestations include dyspnea, aspiration pneumonia, and respiratory failure. Gastrointestinal manifestations include nausea, vomiting, diarrhea, and bloating. No specific antidote for lithium poisoning is known

.

The risk of lithium toxicity is increased by:

Recent onset of concurrent febrile illness

Concomitant administration of drugs which increase lithium serum concentrations by pharmacokinetic interactions or drugs affecting kidney function . …

Lithium side effects

The following adverse reactions are described in greater detail in other sections:

Acute Lithium Toxicity

Lithium-Induced Polyuria

Hyponatremia

Lithium-Induced Chronic Kidney Disease

Encephalopathic Syndrome

Serotonin Syndrome

Hypothyroidism or Hyperthyroidism

Hypercalcemia and Hyperparathyroidism

Unmasking of Brugada Syndrome

Pseudotumor Cerebri

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Pediatric Patients (7 to 17 years):

Bipolar I Disorder:The following findings are based on an 8-week, placebo-controlled study for acute manic or mixed episodes of bipolar I disorder in pediatric patients 7 to 17 years (N= 81). In this study, lithium was administered at daily doses ranging from 300 to 3600 (mean dose 1483 mg ± 584) with serum levels ranging from 0 to 2.0 (mean level 0.98 mEq/L ± 0.47).

Common Adverse Reactions (incidence ≥ 5% and at least twice the rate of placebo):

nausea/vomiting, polyuria, thyroid abnormalities, tremor, thirst/polydipsia, dizziness, rash/dermatitis, ataxia/gait disturbance, decreased appetite, and blurry vision. …

Drug interactions

Table 4: Clinically Important Drug Interactions with Lithium

Diuretics

Clinical Impact: | Diuretic-induced sodium loss may reduce lithium clearance and increase serum lithium concentrations.

Intervention: | More frequent monitoring of serum electrolyte and lithium concentrations. Reduce lithium dosage based on serum lithium concentration and clinical response

.

Non-Steroidal Anti-inflammatory Drugs (NSAID)

Clinical Impact: | NSAID decrease renal blood flow, resulting in decreased renal clearance and increased serum lithium concentrations.

Intervention: | More frequent serum lithium concentration monitoring. Reduce lithium dosage based on serum lithium concentration and clinical response

.

Renin-Angiotensin System Antagonists

Clinical Impact: | Concomitant use increase steady-state serum lithium concentrations.

Intervention: | More frequent monitoring of serum lithium concentration. Reduce lithium dosage based on serum lithium concentration and clinical response

.

Serotonergic Drugs

Clinical Impact: | Concomitant use can precipitate serotonin syndrome.

Intervention: | Monitor patients for signs and symptoms of serotonin syndrome, particularly during lithium initiation. If serotonin syndrome occurs, consider discontinuation of lithium and/or concomitant serotonergic drugs

. …

About this medicine

Each 5 mL of

solutionfor oral administration contains lithium ion (Li

+), 8 mEq (equivalent to amount of lithium in 300 mg of lithium carbonate), alcohol 0.3% v/v and the following other inactive ingredients: citric acid, purified water, artificial cherry flavor, sodium benzoate and sorbitol solution. May also contain sodium hydroxide for pH adjustment.

Lithium oral solution, USP is a palatable oral dosage form of lithium ion. It is prepared in solution from trilithium citrate tetrahydrate and citric acid in a ratio approximately di-lithium citrate.

Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer.

The empirical formula for Lithium Citrate is C

6H

5Li

3O

7; molecular weight 209.93. Lithium acts as an antimanic.

How it works: The mechanism of action of lithium as a mood stabilizing agent is unknown. Absorption: After oral administration, lithium is reported to be completely absorbed in the upper gastrointestinal tract. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID be1346df-4a39-45e8-874b-e2a496847fd5. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone